3046 Moclobemide Moclobemide is only found in individuals that have used or taken this drug. It is a reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms. 71320-77-9 4235 C13H17ClN2O2 268.097860 White powder. 1.12e+00 g/L Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration. The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms. Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6. Half Life: 1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted LD50: 730mg/kg (Mouse) (A308) LD50: 1300mg/kg (Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the treatment of depression. 2009-07-21T20:28:31Z 2014-12-24T20:25:55Z Moclobemide 239099 Moclobemide DB01171 true ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1 C13H17ClN2O2 InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17) InChIKey=YHXISWVBGDMDLQ-UHFFFAOYSA-N 268.739 268.097855505 Exogenous Solid 1.5 HMDB15302 CHEMBL86304 4087